Access the resources below for additional details about RUKOBIA, including the challenges of heavily treatment-experienced (HTE) adults with HIV-1 and who are failing their current therapy, its mechanism of action, information about the BRIGHTE trial, dosing and drug interactions, and the full Prescribing Information.
RUKOBIA National Broadcast
On the panel are Dr. Bruce Gilliam, Dr. Max Lataillade, Dr. Anthony Mills, and Dr. Charlotte-Paige Rolle.
BRIGHTE Educational Series
INTRODUCTION TO HTE PATIENTS
Consider challenges faced by HTE patients with multidrug resistance and limited antiretroviral (ARV) options
NOVEL MECHANISM OF ACTION
Discover a first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells1-3
BRIGHTE CLINICAL TRIAL
See results from a pivotal Phase 3 trial evaluating the efficacy and safety of RUKOBIA in HTE patients
DOSING AND DRUG INTERACTIONS
Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA
- Data on file, ViiV Healthcare.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated June 3, 2021. Accessed June 7, 2021. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/guidelines-adult-adolescent-arv.pdf
- Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.